The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Uterine Fibroids Market Research Report 2025
Synopsis
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
The global Uterine Fibroids market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
This report aims to provide a comprehensive presentation of the global market for Uterine Fibroids, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Uterine Fibroids.
Report Scope
The Uterine Fibroids market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Uterine Fibroids market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Uterine Fibroids companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boston Scientific
Cooper Surgical
C.R. Bard
F. Hoffmann-La Roche
GE Healthcare
Karl Storz Endoscopy
Richard Wolf Medical Instruments
Siemens Medical Solutions
AbbVie
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Pfizer
Johnson & Johnson
Novartis
Segment by Type
Non-Hormonal Treatment
Hormonal Treatment
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Uterine Fibroids companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
The global Uterine Fibroids market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
This report aims to provide a comprehensive presentation of the global market for Uterine Fibroids, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Uterine Fibroids.
Report Scope
The Uterine Fibroids market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Uterine Fibroids market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Uterine Fibroids companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boston Scientific
Cooper Surgical
C.R. Bard
F. Hoffmann-La Roche
GE Healthcare
Karl Storz Endoscopy
Richard Wolf Medical Instruments
Siemens Medical Solutions
AbbVie
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Pfizer
Johnson & Johnson
Novartis
Segment by Type
Non-Hormonal Treatment
Hormonal Treatment
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Uterine Fibroids companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Fibroids Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Non-Hormonal Treatment
1.2.3 Hormonal Treatment
1.3 Market by Application
1.3.1 Global Uterine Fibroids Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Uterine Fibroids Market Perspective (2019-2030)
2.2 Uterine Fibroids Growth Trends by Region
2.2.1 Global Uterine Fibroids Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Uterine Fibroids Historic Market Size by Region (2019-2024)
2.2.3 Uterine Fibroids Forecasted Market Size by Region (2025-2030)
2.3 Uterine Fibroids Market Dynamics
2.3.1 Uterine Fibroids Industry Trends
2.3.2 Uterine Fibroids Market Drivers
2.3.3 Uterine Fibroids Market Challenges
2.3.4 Uterine Fibroids Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Uterine Fibroids Players by Revenue
3.1.1 Global Top Uterine Fibroids Players by Revenue (2019-2024)
3.1.2 Global Uterine Fibroids Revenue Market Share by Players (2019-2024)
3.2 Global Uterine Fibroids Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Uterine Fibroids Revenue
3.4 Global Uterine Fibroids Market Concentration Ratio
3.4.1 Global Uterine Fibroids Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Fibroids Revenue in 2023
3.5 Uterine Fibroids Key Players Head office and Area Served
3.6 Key Players Uterine Fibroids Product Solution and Service
3.7 Date of Enter into Uterine Fibroids Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Uterine Fibroids Breakdown Data by Type
4.1 Global Uterine Fibroids Historic Market Size by Type (2019-2024)
4.2 Global Uterine Fibroids Forecasted Market Size by Type (2025-2030)
5 Uterine Fibroids Breakdown Data by Application
5.1 Global Uterine Fibroids Historic Market Size by Application (2019-2024)
5.2 Global Uterine Fibroids Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Uterine Fibroids Market Size (2019-2030)
6.2 North America Uterine Fibroids Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Uterine Fibroids Market Size by Country (2019-2024)
6.4 North America Uterine Fibroids Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Uterine Fibroids Market Size (2019-2030)
7.2 Europe Uterine Fibroids Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Uterine Fibroids Market Size by Country (2019-2024)
7.4 Europe Uterine Fibroids Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Uterine Fibroids Market Size (2019-2030)
8.2 Asia-Pacific Uterine Fibroids Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Uterine Fibroids Market Size by Region (2019-2024)
8.4 Asia-Pacific Uterine Fibroids Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Uterine Fibroids Market Size (2019-2030)
9.2 Latin America Uterine Fibroids Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Uterine Fibroids Market Size by Country (2019-2024)
9.4 Latin America Uterine Fibroids Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Uterine Fibroids Market Size (2019-2030)
10.2 Middle East & Africa Uterine Fibroids Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Uterine Fibroids Market Size by Country (2019-2024)
10.4 Middle East & Africa Uterine Fibroids Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boston Scientific
11.1.1 Boston Scientific Company Detail
11.1.2 Boston Scientific Business Overview
11.1.3 Boston Scientific Uterine Fibroids Introduction
11.1.4 Boston Scientific Revenue in Uterine Fibroids Business (2019-2024)
11.1.5 Boston Scientific Recent Development
11.2 Cooper Surgical
11.2.1 Cooper Surgical Company Detail
11.2.2 Cooper Surgical Business Overview
11.2.3 Cooper Surgical Uterine Fibroids Introduction
11.2.4 Cooper Surgical Revenue in Uterine Fibroids Business (2019-2024)
11.2.5 Cooper Surgical Recent Development
11.3 C.R. Bard
11.3.1 C.R. Bard Company Detail
11.3.2 C.R. Bard Business Overview
11.3.3 C.R. Bard Uterine Fibroids Introduction
11.3.4 C.R. Bard Revenue in Uterine Fibroids Business (2019-2024)
11.3.5 C.R. Bard Recent Development
11.4 F. Hoffmann-La Roche
11.4.1 F. Hoffmann-La Roche Company Detail
11.4.2 F. Hoffmann-La Roche Business Overview
11.4.3 F. Hoffmann-La Roche Uterine Fibroids Introduction
11.4.4 F. Hoffmann-La Roche Revenue in Uterine Fibroids Business (2019-2024)
11.4.5 F. Hoffmann-La Roche Recent Development
11.5 GE Healthcare
11.5.1 GE Healthcare Company Detail
11.5.2 GE Healthcare Business Overview
11.5.3 GE Healthcare Uterine Fibroids Introduction
11.5.4 GE Healthcare Revenue in Uterine Fibroids Business (2019-2024)
11.5.5 GE Healthcare Recent Development
11.6 Karl Storz Endoscopy
11.6.1 Karl Storz Endoscopy Company Detail
11.6.2 Karl Storz Endoscopy Business Overview
11.6.3 Karl Storz Endoscopy Uterine Fibroids Introduction
11.6.4 Karl Storz Endoscopy Revenue in Uterine Fibroids Business (2019-2024)
11.6.5 Karl Storz Endoscopy Recent Development
11.7 Richard Wolf Medical Instruments
11.7.1 Richard Wolf Medical Instruments Company Detail
11.7.2 Richard Wolf Medical Instruments Business Overview
11.7.3 Richard Wolf Medical Instruments Uterine Fibroids Introduction
11.7.4 Richard Wolf Medical Instruments Revenue in Uterine Fibroids Business (2019-2024)
11.7.5 Richard Wolf Medical Instruments Recent Development
11.8 Siemens Medical Solutions
11.8.1 Siemens Medical Solutions Company Detail
11.8.2 Siemens Medical Solutions Business Overview
11.8.3 Siemens Medical Solutions Uterine Fibroids Introduction
11.8.4 Siemens Medical Solutions Revenue in Uterine Fibroids Business (2019-2024)
11.8.5 Siemens Medical Solutions Recent Development
11.9 AbbVie
11.9.1 AbbVie Company Detail
11.9.2 AbbVie Business Overview
11.9.3 AbbVie Uterine Fibroids Introduction
11.9.4 AbbVie Revenue in Uterine Fibroids Business (2019-2024)
11.9.5 AbbVie Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Detail
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Uterine Fibroids Introduction
11.10.4 AstraZeneca Revenue in Uterine Fibroids Business (2019-2024)
11.10.5 AstraZeneca Recent Development
11.11 Bayer
11.11.1 Bayer Company Detail
11.11.2 Bayer Business Overview
11.11.3 Bayer Uterine Fibroids Introduction
11.11.4 Bayer Revenue in Uterine Fibroids Business (2019-2024)
11.11.5 Bayer Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Uterine Fibroids Introduction
11.12.4 Eli Lilly Revenue in Uterine Fibroids Business (2019-2024)
11.12.5 Eli Lilly Recent Development
11.13 GlaxoSmithKline Pharmaceuticals
11.13.1 GlaxoSmithKline Pharmaceuticals Company Detail
11.13.2 GlaxoSmithKline Pharmaceuticals Business Overview
11.13.3 GlaxoSmithKline Pharmaceuticals Uterine Fibroids Introduction
11.13.4 GlaxoSmithKline Pharmaceuticals Revenue in Uterine Fibroids Business (2019-2024)
11.13.5 GlaxoSmithKline Pharmaceuticals Recent Development
11.14 Pfizer
11.14.1 Pfizer Company Detail
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Uterine Fibroids Introduction
11.14.4 Pfizer Revenue in Uterine Fibroids Business (2019-2024)
11.14.5 Pfizer Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Detail
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Uterine Fibroids Introduction
11.15.4 Johnson & Johnson Revenue in Uterine Fibroids Business (2019-2024)
11.15.5 Johnson & Johnson Recent Development
11.16 Novartis
11.16.1 Novartis Company Detail
11.16.2 Novartis Business Overview
11.16.3 Novartis Uterine Fibroids Introduction
11.16.4 Novartis Revenue in Uterine Fibroids Business (2019-2024)
11.16.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
